The Activin Receptor Like Kinase pipeline drugs market research report outlays comprehensive information on the Activin Receptor Like Kinase targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Activin Receptor Like Kinase pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Musculoskeletal Disorders, Hematological Disorders, Oncology, and Metabolic Disorders which include the indications Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), Post Menopausal Osteoporosis, Iron Deficiency Anemia, Anemia, Myelofibrosis, Post-Polycythemia Vera Myelofibrosis (PPV-MF), and Obesity. It also reviews key players involved in Activin Receptor Like Kinase targeted therapeutics development with respective active and dormant or discontinued products.
The Activin Receptor Like Kinase pipeline targets constitutes close to 17 molecules. Out of which, approximately 14 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase II, IND/ CTA Filed, and Preclinical stages are 1, 3, 1, and 9 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 2, and 1 molecule.
Activin Receptor Like Kinase overview
Activin receptor like kinases (ALKs) are a group of seven type I receptors responsible for TGF-beta family signal transduction and are utilized by many ligands within the superfamily. ALKs exert regulatory roles in cell differentiation, proliferation, apoptosis, invasion, and migration, and mutation of ALKs results in various human cancers.
For a complete picture of Activin Receptor Like Kinase’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
